318 related articles for article (PubMed ID: 30317986)
21. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
22. Emerging biologic therapies for hypercholesterolaemia.
Pucci G; Cicero AF; Borghi C; Schillaci G
Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
[TBL] [Abstract][Full Text] [Related]
23. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.
Liberale L; Montecucco F; Camici GG; Dallegri F; Vecchie A; Carbone F; Bonaventura A
Curr Med Chem; 2017; 24(14):1403-1416. PubMed ID: 28260498
[TBL] [Abstract][Full Text] [Related]
24. Regulation of PCSK9 by nutraceuticals.
Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
[TBL] [Abstract][Full Text] [Related]
25. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
26. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove.
Evison BJ; Palmer JT; Lambert G; Treutlein H; Zeng J; Nativel B; Chemello K; Zhu Q; Wang J; Teng Y; Tang W; Xu Y; Rathi AK; Kumar S; Suchowerska AK; Parmar J; Dixon I; Kelly GE; Bonnar J
Bioorg Med Chem; 2020 Mar; 28(6):115344. PubMed ID: 32051094
[TBL] [Abstract][Full Text] [Related]
27. Bococizumab for the treatment of hypercholesterolaemia.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Expert Opin Biol Ther; 2017 Feb; 17(2):237-243. PubMed ID: 28060539
[TBL] [Abstract][Full Text] [Related]
28. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ; Dent R; Castro RC; Toth PP
Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
[TBL] [Abstract][Full Text] [Related]
29. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
30. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M
Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067
[TBL] [Abstract][Full Text] [Related]
31. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
Schmitz J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1484-1494. PubMed ID: 28137217
[TBL] [Abstract][Full Text] [Related]
32. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
[TBL] [Abstract][Full Text] [Related]
33. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
[TBL] [Abstract][Full Text] [Related]
34. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou S; Ray KK
Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
[TBL] [Abstract][Full Text] [Related]
35. Safety of PCSK9 inhibitors.
Grześk G; Dorota B; Wołowiec Ł; Wołowiec A; Osiak J; Kozakiewicz M; Banach J
Biomed Pharmacother; 2022 Dec; 156():113957. PubMed ID: 36411665
[TBL] [Abstract][Full Text] [Related]
36. PCSK9: from biology to clinical applications.
Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G
Pathology; 2019 Feb; 51(2):177-183. PubMed ID: 30522786
[TBL] [Abstract][Full Text] [Related]
37. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries.
Nishikido T; Ray KK
Front Cardiovasc Med; 2018; 5():199. PubMed ID: 30761308
[TBL] [Abstract][Full Text] [Related]
38. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
Eisen A; Giugliano RP
Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
40. Cholesterol and stroke: Roll of PCSK9 inhibitors.
Castilla-Guerra L; Fernández-Moreno MC; Rico-Corral MA
Neurologia (Engl Ed); 2019 Apr; 34(3):198-203. PubMed ID: 28549755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]